Healthdyne takeover fight goes to court
This article was originally published in Clinica
A US court could rule this week on a key element of Invacare's long-running hostile takeover bid for Healthdyne Technologies. At stake at the federal court hearing will be whether Healthdyne's anti-takeover defence mechanism should be overturned to allow shareholders to vote on new directors who support Invacare, says Invacare lawyer Mark Harnett. Invacare has asked for an expedited ruling prior to Healthdyne's annual meeting on July 30.
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.